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Abstract The cystic fibrosis transmembrane conductance
regulator (CFTR) is responsible for the disease cystic
fibrosis (CF). It is a membrane protein belonging to the
ABC transporter family functioning as a chloride/anion
channel in epithelial cells around the body. There are over
1500 mutations that have been characterised as CF-caus-
ing; the most common of these, accounting for *70 % of
CF cases, is the deletion of a phenylalanine at position 508.
This leads to instability of the nascent protein and the
modified structure is recognised and then degraded by the
ER quality control mechanism. However, even pharmaco-
logically ‘rescued’ F508del CFTR displays instability at
the cell’s surface, losing its channel function rapidly and it
is rapidly removed from the plasma membrane for lyso-
somal degradation. This review will, therefore, explore the
link between stability and structure/function relationships
of membrane proteins and CFTR in particular and how
approaches to study CFTR structure depend on its stability.
We will also review the application of a fluorescence
labelling method for the assessment of the thermostability
and the tertiary structure of CFTR.
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Introduction
Cystic fibrosis transmembrane conductance regulator
(CFTR) is unique among ABC transporters as it is the only
member of this family of membrane proteins to act as an
ion channel (although two ABC proteins (SUR1 and
SUR2) regulate a potassium channel rather than act as
transporters [1, 2]). As expected, the cystic fibrosis trans-
membrane conductance regulator (CFTR) follows the same
domain structure as other ABC transporters (Fig. 1): it has
two nucleotide-binding domains (NBDs) in tandem with
two transmembrane domains (TMDs). What differentiates
it from the other transporters (apart from its channel
activity) is its regulatory domain or ‘R’ region (the word
‘region’ is suggested by Forman-Kay and co-workers as
this 200-amino acid-long region is largely unstructured
when analysed in isolation by NMR [3]). The R-region lies
between the first TMD and the second NBD, within the
cytoplasm. There is no significant sequence homology
between the R-region and any other proteins in nature;
hence, its origins are obscure. Within the ABC family, only
ABCA1 in higher plants has a connecting region of similar
length, and this is enriched in charged residues, like the
CFTR R-region.
The R-region contains a number of Protein Kinase A
(PKA) phosphorylation sites which have been shown to be
highly conserved across species [4] PKA is a cAMP-acti-
vated kinase and as cellular levels of cAMP increase, PKA
phosphorylates CFTR. In a readily understood model, the
R-region is proposed to block the NBDs from associating
together which subsequently keeps the channel in a closed
conformation. Phosphorylation causes a structural change
that removes the R-region from its steric-interfering posi-
tion and allows NBD dimerisation to occur, triggering a
much larger conformational change (Fig. 1). It is then the
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binding of ATP that is thought to initiate channel opening
whilst channel closure is associated with ATP hydrolysis
and release of ADP and inorganic phosphate [5, 6]. For-
man-Kay and co-workers have proposed a more complex
model involving the C-terminal region [7], which also
displays a sequence unique to CFTR. In this model,
phosphorylation of the R-region causes a switch from it
interacting with the NBDs to it interacting with the C-ter-
minal region. In this scenario the R-region acts as a global
regulator of CFTR via its alternative interacting partners
[7].
The effects on stability of F508 deletion
Cystic fibrosis is caused by mutation in the CFTR protein.
There are estimated to be over 1800 different mutations
that can lead to cystic fibrosis (http://www.genet.sickkids.
on.ca). Of these, the deletion of phenylalanine at position
508 is by far the most common and 95 % of CF patients
possess at least one allele with this mutation. Homozygous
F508del patients account for 65–70 % of cystic fibrosis
cases in some groupings [8] and they have almost complete
loss of the protein at the apical membrane. These patients
have the most severe form of the disease. Heterozygous
individuals (carriers), with one WT gene and one F508del
mutated gene, have no symptoms and there may have been
some selective advantage in the past for such individuals—
such as reduced water loss in diarrhea. This has led to a
theory that the prevalence of this mutation in certain
populations is due to the increased resistance to dehydra-
tion-causing diseases such as cholera and typhoid fever
which were previously major causes of morbidity, espe-
cially in infancy [9].
The F508del mutation and its effect on the stability and
function of the protein have been studied extensively
[10–14]. The deletion of phenylalanine at position 508 is
crucial due to the position of this residue in the tertiary
structure of the protein. It probably lies at the connecting
position between the helical sub-domain of NBD1 and the
second cytoplasmic loop of TMD2, a conclusion based on
homology modelling [15] as well as cross-linking studies
[8, 16, 17]. As a result of the mutation, there is thought to
be a less stable conformation between TMD2 and NBD1,
resulting in a protein that is recognisable by ER chaperones
and which is then degraded by the ER quality control
system via ubiquitinylation and proteasome-mediated
degradation [18–20].
Cui et al. also considered the defect of F508del in terms
of a different set of domain interactions [21]. They pro-
posed that F508 deletion has an effect early in the folding
of the protein and that the interaction between NBD1 and
Fig. 1 Cartoon illustrating how ATP binding and subsequent hydrolysis could lead to channel opening and flux of chloride ions (based on the
model proposed by Wang et al. [3])
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TMD1 is stabilised by this residue. These conclusions were
based on the observation of a defined TMD1-NBD1 unit
that was resistant to exogenously added protease in the WT
protein, but not in the F508del version. This early unit in
the CFTR folding pathway was proposed to be sufficient to
escape endoplasmic reticulum quality control. If the
F508del CFTR protein arrives at the apical membrane of
the epithelial cell, it exhibits a reduced functionality as a
chloride channel [22] and is susceptible to degradation.
Two problems are thus associated with the mutated protein,
a reduced migration to the apical membrane of the cell and
the limited amount of protein that is found at the membrane
has a highly reduced gating functionality. Treatments
aimed at combating both of these defects have been con-
sidered [14].
Treatments affecting the stability defect
The first indication of a potential therapeutic method was
reported by Denning et al. [23]. Their results showed,
with cells from two different expression systems, that the
induction of expression of F508del CFTR at lower growth
temperatures gave a much greater amount of fully gly-
cosylated protein (the so-called ‘Band C’, migrating with
a roughly 25 kDa higher relative mass on SDS-PAGE gels
is extensively glycosylated). They suggested that some of
the mutated protein had escaped the usual endoplasmic
reticulum quality control step and had been correctly
glycosylated and had proceeded to the plasma membrane.
Perhaps for the first time these results highlighted the role
of thermal stability in the correct processing of full-length
CFTR. Shortly after this, work by Sato et al. [24] showed
that F508del-CFTR-expressing cells, when exposed to
10 % glycerol, increase their expression of the mutant
protein. These results included immunoblotting of the
mature, fully glycosylated protein after pulse chase and
patch clamp recordings of the cells which identified an
increase in chloride conductance. This discovery, along-
side that of Denning and co-workers [23], illustrated that
the instability/misfolding of F508del-CFTR can be
reversibly corrected by either lowered thermal energetics
of the protein, or by the inclusion of a molecular chap-
erone such as glycerol. Although glycerol treatment
cannot be translated therapeutically, the work highlighted
that development of small-molecule correctors of the
instability/folding defect might achieve pharmacological
practicality. It is now 20 years after these studies, and
there has been the discovery of a number of pharmaco-
logical correctors aimed at treatment of the F508del
mutation [25]. For example, compounds have been pro-
duced that affect the F508del-CFTR interactome including
the proteasome complex that leads to degradation of the
protein and chaperones that specifically bind to the
F508del-CFTR peptide [13, 26, 27].
One of the earliest pharmacological groups of com-
pounds to be discovered was that of the tricyclic
benzo[c]quinoliziniums or MPB compounds [28]. These
were originally deduced as activators of the CFTR channel.
A further study of these compounds carried out by Dormer
et al. [29] revealed that application of a derivative of the
original compounds, MPB-07, resulted in increased deliv-
ery of CFTR to the apical membrane, similar to the amount
seen in wild-type cells. This was shown to be as a result of
the prevention of normal degradation of the mutated pro-
tein, allowing for increased, yet unstable CFTR to make its
way to the apical membrane.
Some of the first pharmacological chaperones discov-
ered through high-throughput drug screening were reported
by Pedemonte et al. [30]. Four classes of molecules were
found by this group of workers, each showing some effi-
cacy in helping to re-fold CFTR. Out of the four classes of
molecules, two showed significant efficacy in promoting an
increased amount of F508del-CFTR to the plasma mem-
brane. Those of the bisaminomethylbithiazoles, class 4,
were found to be the most effective. Two particular
molecules, corr-4a and corr-4c, when incubated with
CFTR-expressing Fischer Rat Thyroid (FRT) cells, showed
an increased efficiency of CFTR folding as well as stabil-
isation of the protein. Classes 2 and 4 are both thought to
be proteostasis regulators [31], due to their effect on either
the endoplasmic reticulum quality control (class 4) or the
lysosome-mediated degradation quality control system
(class 2). Only class 4 molecules showed efficacy in pri-
mary bronchial epithelial cells which would be the primary
target cell in the diseased lungs.
Pedemonte and co-workers went on to explore the class
2 molecules identified in the original screening; this led to
identification of a particular group of compounds called
aminoariathiozoles (AATs). These compounds showed
enhanced channel trafficking and improved gating; this was
seen as a promising result due to the fact that a potentiator
would no longer be required in addition to a corrector.
However, a further study involving these compounds failed
to produce a statistically significant result in primary
bronchial epithelial cells [32]. A number of studies have
similarly fallen short in finding molecules that are effective
in vivo.
Van Goor et al. [33] described a corrector compound
with efficacy in human bronchial epithelial cells, a quina-
zolinone derivative, VRT-325. From their study, they
showed that the drug also aided the expression of other
mutant forms of CFTR. Further optimisation from this
screen led to one of the most successful correctors to be
developed [34]. When tested in cultured primary human
bronchial epithelial cells, VX-809 increased chloride
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transport to that of 14 % of non-CF (HBE). Most impor-
tantly, this was enough to produce an increase in the
thickness of the airway surface liquid (ASL) which shows a
high clinical importance [35].
VX-809 did show some efficacy in Phase IIa clinical
trials carried out by Clancy et al. [36]. These studies show a
reduced sweat chloride concentration indicating that VX-
809 is active in that particular organ. However, reduced
sweat chloride is only a biomarker; it does not improve
quality of life. A desired clinical outcome in CF patients
would be improved lung function. This particular study
proved that VX-809 has an acceptable safety profile and
provided a foundation for an increase of the study on the
particular drug.
Farinha, CM et al. [37] have shown that out of the three
correctors currently developed: VRT-325, VX-809 and C4,
VX-809 has been shown to be the most effective in
increasing protein accumulation to the plasma membrane.
Compared to VRT-325 and C4 in primary HBE cells, a
higher production of F508del-CFTR was found with the
use of VX-809. However, despite the promising results
gained from VX-809, the rescuing effect was not high
enough to restore CFTR function to wild-type levels.
Cystic fibrosis symptoms may be prevented with as little as
25 % delivery of CFTR to epithelial cells, and certainly
heterozygous individuals with presumably 50 % CFTR
levels are unaffected. Synergistic trials were undertaken to
try to increase the rescuing effect of VX-809 by applying
another drug in the presence of VX-809. VX-770 is an
FDA authorised potentiator drug, used to correct the gating
defect present in the CFTR G551D mutation. This restores
the channel into an open state which allows chloride con-
duction across the membrane where previously the G551D
mutation resulted in a constitutively closed formation. Two
recent studies have explored the use of VX-770 in com-
bination with VX-809 to potentially increase the efficacy of
VX-809’s rescue of F508del-CFTR to the plasma
membrane.
Sampson et al. [38] showed development of a pharma-
cological chaperone corrector; that is, a compound that
binds to the CFTR protein itself and stabilises the inter-
action between NBD1 and the TMD1. Despite no further
work being carried out on the compound to date, Sampson
and co-workers’ study provides somewhat of a scaffold for
future pharmacological chaperone development. In partic-
ular, they identify a terminal phenyl ring which they
postulate to be necessary for interaction with the nucleo-
tide-binding domain.
VX-661 is another promising pharmacological chaper-
one, an improved version of VX-809, which has shown
improved lung function among homozygous F508del-
CFTR patients in a phase II trial. Vertex Pharmaceuticals
has announced the compound to be used in triple
combination trials with newly developed correctors, VX-
440 and VX-152, both of which are thought to have a
positive effect on the processing and trafficking of the
CFTR protein leading to a higher yield at the cell surface.
Despite the positive data achieved from Vertex’s com-
pounds, VX-770 has been shown to reduce the therapeutic
effect of established CFTR chaperones. Two studies by
Veit et al. [39] and Cholon et al. [40] have shown evidence
which would suggest that VX-770 biochemically desta-
bilises F508del-CFTR, thus reversing the effect of current
correctors, VX-809 and VX-661. Although these are both
in vitro studies and do not contradict the slight alleviation
of CF symptoms by VX-809-derived treatments, discovery
of new pharmacological correctors is probably required to
ensure more effective treatment of the F508del mutation. A
revised strategy to ensure effective drug discovery is also
required, involving methods which increase the stability of
the nascent protein, allowing it to progress to the plasma
membrane. A compound of this nature will then suitably
work in combination with VX-770 or another potentiator to
maintain an effective amount of CFTR-F508del at the
plasma membrane.
As renewed efforts are made towards the development
of pharmacological compounds, assays of protein stability
will be important to determine the efficacy of corrector
compounds. One could argue that the more stable the
protein, the less likely it will be to unfold and the more
likely it will be that it will escape the ER quality control
steps. On the other hand, the global thermodynamic sta-
bility of the mutated protein may be irrelevant if the
primary defect is at the early stages of protein folding.
Although data on low-temperature rescue of F508del
CFTR and its subsequent residence time at the plasma
membrane point to the likelihood of a global thermody-
namic defect, there remains the possibility that a specific
step in the folding pathway is disrupted. To address this,
studies on the stability and structure of purified CFTR are
desirable, and this will be addressed in the next section.
Membrane proteins and the importance of stability
for expression, purification and structural studies
Membrane proteins compose a significant fraction of the
number of different proteins in the cell, and represent a
disproportionately large fraction of the molecular targets of
current drugs used to treat human disease. However,
membrane proteins are vastly under-represented in the
databases of protein structures [41]. This deficit in infor-
mation is due to difficulties in membrane protein
expression, purification and structure determination.
Membrane protein expression is fundamentally limited
by available membrane area in the cell and by the capacity
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of the co-translational membrane insertion machinery. As a
result, overproduction of membrane proteins like CFTR
where membrane capacity is exceeded can lead to the
production of aggregates in the cell that are highly resistant
to detergent solubilisation and purification [42–44].
Purification is limited by the requirement for solubili-
sation of the membranes with detergent and then the need
for detergent to be present throughout the subsequent
fractionation processes [45]. The detergent may only par-
tially solubilise the protein (if a ‘mild’ detergent is used) or
may solubilise effectively but at the same time denature the
protein (if a ‘harsh’ detergent is used [46, 47].
If a non-denatured protein can be purified, structural
studies are still limited by the need for long-term stability
of the tertiary and/or quaternary structure in the detergent,
especially for NMR studies where the experiment will be
performed well above 4 C to increase the tumbling rate
[48]. Moreover, the presence of the detergent belt sur-
rounding the protein can interfere with the structure
determination. For NMR studies the micelle belt increases
the size of the protein/detergent complex and reduces
tumbling speed, with consequently broadened signals [48].
This has led to a bias in the range of detergents that have
been used for NMR structures of membrane proteins
(http://www.drorlist.com/nmr/MPNMR.html) with those
forming small micelles being favoured. For X-ray crys-
tallographic studies, the micelle must be accommodated
within the crystal lattice without interfering with lattice
contacts, hence must also be small and perhaps deformable.
It is probably for this reason that membrane protein crystals
are biased towards relatively high solvent contents—that is
they have an open lattice that can accommodate the pres-
ence of the detergent micelle [49]. For single particle cryo-
electron microscopy (cryo-EM) studies, the detergent
micelle can be visualised as a weaker/diffuse band of
density around the protein [50]. It is not yet clear whether
this reduces the effectiveness of the cryo-EM approach, but
the background presence of free detergent micelles can
reduce contrast and the efficiency of single particle align-
ment steps in the 3D reconstruction procedure. For small-
angle X-ray scattering studies (SAXS), the micelle’s scat-
tering needs to be divorced from the protein scattering to
generate reasonable models which require a series of
painstaking experiments with different solvent composi-
tions so that either the protein or the detergent scattering
component can be contrast-matched to remove its contri-
bution to the scattering curve [51]. Similar approaches are
employed for neutron scattering studies, but here the con-
trast is adjusted by varying the D2O to H2O ratio [52].
Stability Many of these difficulties for membrane pro-
tein structure determination can be influenced by the
stability of the protein. For example, a relatively unsta-
ble membrane protein such as CFTR may be recognised as
such by the host cell’s quality control machinery and
degraded [14]. Similarly, an unstable protein is likely to
have any instability accentuated by the presence of a
detergent micelle; indeed the detergent may affect the
membrane protein’s soluble domains as well as the trans-
membrane domains [53]. Locally unstable regions of the
protein in domains normally exposed to the aqueous milieu
may give poor water solubility during purification because
hydrophobic residues that are normally buried in the ter-
tiary fold will become exposed with a concomitant chance
of forming polydisperse aggregates, especially at high
protein concentrations [45, 54, 55]. Monodispersity is a
strict requirement for structure generation from NMR and
SAXS experiments, and is usually a pre-requisite for
obtaining 3D crystals that diffract X-rays to high resolution
[45, 56]. For single particle cryo-EM, monodispersity is
also desirable, but is less strictly required for structure
determination, especially if polydisperse aggregates can be
readily distinguished from the non-aggregated monomeric
or oligomeric particle [57]. Single particle cryo-EM and, to
a similar extent, SAXS do not require high protein solu-
bility for structure determination as they are compatible
with protein concentrations below 1 mg/mL. However,
NMR and X-ray crystallography usually require the con-
centration of the protein to be greater than 5 mg/mL.
Thus, the effects of the stability of a protein on its water
solubility as well as its monodispersity properties are cru-
cial for most structural biology techniques, with the
possible exception of cryo-EM which is more tolerant of
some polydispersity and does not require high water sol-
ubility of the protein. However, cryo-EM and SAXS-
derived structures have typically been at much lower res-
olution than those obtained by X-ray crystallography and
NMR. This is likely to change in the next few years for the
cryo-EM technique with the introduction of new detection
devices and software [58, 59]. Finally, it is possible that a
membrane protein may adopt a non-native state that may
still crystallise and generate a structure [60]. Thus, deter-
gents and stability may be a factor even where structures
are present in the protein data bank.
Measures of protein stability
For many membrane proteins, stability can be measured
simply by detecting the activity of the protein as a function of
time, temperature or denaturant concentration. For example,
crystallisation ofGprotein-coupled receptor familymembers
has been achieved by finding stabilising mutations, with
stability assessed by measuring radioactive ligand binding as
a function of temperature [61]. For proteins without an
obvious activity read-out, or where activity measurements
require excessive amounts of purified protein, alternative
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biophysical measures of stability are available. Biophysical
methods such as small-angle X-ray scattering, differential
scanning calorimetry and circular dichroism have been well
described and are generally easily interpretable, but have the
drawback of consuming significant amounts of purified pro-
tein. Fluorescence methods are particularly useful for
membrane proteins because of sensitivity, avoiding the
consumption of large amounts of protein. Intrinsic fluores-
cence, where the differential properties of buried versus
water-exposed tryptophan residues canbe exploited, has been
employed with membrane proteins, but the approach is
hampered by the presence of detergent micelles or liposomes
(where the protein has been reconstituted) [62]. Adding flu-
orescent probes has also been employed to measure
membrane protein stability, although again, the presence of
detergents or lipid complicates the interpretation of the data.
The efficacy of three of the most commonly employed fluo-
rescent reporters with two different purified membrane
proteins was recently compared [63], and this provides a
useful assessment of the methodology as applied to mem-
brane proteins. Of note was that the cysteine (Cys)-reactive
reporter 7-diethylamino-3-(40-maleimidylphenyl)-4-methyl-
coumarin (CPM)was capable of distinguishing the unfolding
of separate subunits of cytochrome c oxidase. We review the
use of this reporter for CFTR stability measurement later.
Expression and purification of CFTR
and the effects of stability
The expression and purification of CFTR has been reported
previously [54, 64–67]. Challenges in its purification are
manifold and it illustrates many of the problems described
in the previous section. For CFTR, a comparison of con-
structs with different degrees of stability is informative and
shows how this factor affects expression and purification.
As discussed above, F508del CFTR is less stable than the
WT protein, whilst the G551D CFTR mutation locks the
channel in a closed state, and this mutant form of the
protein appears to be more stable than the WT protein.
Comparison of expression levels for these constructs can be
made by monitoring a GFP tag on the C terminus of the
CFTR protein. The degree of GFP fluorescence can be
compared with fluorescence from an intrinsic fluorescent
protein (e.g. yeast mitochondrial succinate dehydrogenase)
to allow the CFTR expression level to be adjusted for cell
density and to allow for variability in the harvesting and
breakage of cells and for any and gel loading errors.
An illustration of such data for the CFTR expression is
shown in Fig. 2. As predicted there is a correlation between
the stability of the construct and levels of protein detected
in the same expression system. G551D CFTR had a much
higher yield than WT or F508del CFTR. It is known that
the potentiator VX-770 is able to restore channel activity to
the G551D CFTR channel and to stimulate channel activity
of WT and F508del CFTR; there is predicted to be a loss of
some stability as a result [40]. A comparison of expression
levels of G551D CFTR in cells treated with and without the
potentiator VX-770 is shown in Fig. 2b. Cells treated
chronically with VX-770 after induction did not show a
reversal to the expression levels of WT CFTR.
Purification of CFTR
CFTR is also an example for how stability can influence
the ability to purify a protein, and detergents used to sol-
ubilise and purify CFTR can be compared. For example,
we can examine the purification of the protein in a mild
detergent and in a harsher anionic detergent:
Purification of CFTR in an anionic lyso-lipid
surfactant: lyso-phosphatidyl glycerol-14 (LPG14)
The anionic detergent, LPG is thought to be less mild in
terms of its surface activity compared to non-ionic deter-
gents [68]. In agreement with this, it was more efficient in
solubilisation and purification. However, functional CFTR
was successfully purified using this detergent [69, 70].
Figure 3 shows a Coomassie-stained SDS-PAGE gel of
G551D CFTR purified using nickel-NTA affinity
Fig. 2 Expression levels are broadly related to stability for CFTR in
S. cerevisiae. Comparison of WT (triangles), G551D (circles) and
F508del (squares) CFTR expression as a function of time after
induction. The fluorescence from the GFP tag attached to CFTR is
compared to that from an endogenous fluorescent protein (endFP,
succinate dehydrogenase) to correct for variability in cell breakage,
microsome preparation and gel loading
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chromatography in 0.1 % LPG. Nearly 90 % of total CFTR
in the microsomes can be solubilised in LPG and its
binding efficiency to the nickel-NTA column can reach
90 % [67]. As a maximum, 20 mg of purified G551D
protein can be obtained from a single 18-L fermenter run,
compared to about 2 mg for WT CFTR [67]. These esti-
mates of efficiency were estimated based on the GFP
fluorescence of the fractions using a fluorometer. This
tenfold increase in final yield of purified G551D protein
compared to wild type [67] is in broad agreement with the
cellular expression levels indicated in Fig. 2. The purity
immediately after nickel-NTA affinity purification has
been reported to reach 95 %, as judged by Coomassie-
stained SDS-PAGE gels, but CFTR protein can then be
injected onto a size-exclusion chromatography (SEC) col-
umn. This also allows monodispersity of the CFTR to be
estimated as well as providing a polishing step for the
purification. A fluorescence detector connected to the outlet
from the SEC column allows the detection of either GFP
fluorescence or tryptophan fluorescence. An illustration of
a purification run is shown in Fig. 3.
Interestingly, the more stable G551D CFTR construct
also seems to be more homogeneous than WT CFTR, as
judged by the relative fluorescence of the larger aggregates
versus monomer peak (Fig. 4). For both G551D and WT
CFTR proteins it is possible to concentrate them using a
100 kDa MWCO membrane concentrator up to 30 mg/mL
in the LPG detergent. In general, the yield of LPG-purified
G551D CFTR is high compared to other eukaryotic
Fig. 3 a Coomassie-stained SDS-PAGE gel of G551D CFTR eluted
from the main peak from the nickel-NTA purification step for protein
extracted and purified with LPG. b SEC purification of WT (red line)
and G551D (blue line) CFTR in LPG. The second peak fractions
(solid lines) were re-injected onto the Sucrose 6 column and the
curves are shown on the same graph, WT (red dashed line) and
G551D (blue dashed line). The inset is an example gel of the
purification procedure. Lanes 1 and 2 are the first and second
fluorescence peak elution fractions. Lane 3 was the re-injected
fluorescence peak elution for G551D CFTR. The intervening track
contains the tail of the first elution peak (monomeric CFTR in small
amounts)
Fig. 4 Coomassie-stained SDS-PAGE gels of (left to right) G551D,
WT and F508del CFTR eluted in the 400 mM imidazole elution step
from the nickel-NTA column for protein extracted and purified with
DDM. The CFTR band (220 kDa) and the main contaminating
protein in each case (RPL3: 44 kDa) are indicated. The intermediate
contaminating band is an abundant yeast membrane protein (plasma
membrane H?-ATPase:100 kDa)
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membrane proteins with the same GFP tag and yeast
expression system [71]. The homogeneity of the protein
and high yield makes it possible to employ biophysical
characterisation methods that demand large amounts of
protein and also to attempt high-resolution structural
studies. For example, both WT and F508del CFTR protein
purified in LPG have been used in small-angle X-ray
scattering studies and for Cryo-EM [51].
Purification of CFTR in a non-ionic detergent:
dodecyl maltoside
DDM is the most commonly used detergent to purify
membrane proteins and it has been the most successful for
crystallisation [72]. Purification methods in both DDM
and LPG are similar, as described in [67]. Figure 4 shows
a comparison of Coomassie-stained SDS-PAGE gels of
CFTR eluted after nickel-NTA affinity purification in
0.1 % DDM. Example gels of G551D, WT and F508del
CFTR (left to right) are given. The main contaminating
protein in the CFTR purification is yeast ribosomal pro-
tein L3 (RPL3, as confirmed by mass spectrometry),
which clearly binds strongly to the Ni–NTA resin, eluting
later than CFTR in a 400 mM imidazole elution step.
Compared to WT CFTR purification, the G551D purifi-
cation again appears to be more efficient, with equivalent
levels of RPL3 present, but considerably higher levels of
the full-length CFTR. WT and F508del CFTR show
similar levels of purity after Ni-NTA affinity purification.
Yields of G551D CFTR after the nickel-NTA affinity
purification with DDM were reported to be about 3–4 mg
from an 18-L fermenter while the yield was typically
lower (2–3 mg) for WT CFTR [67]. The differences
between G551D and WT protein can also be noted at the
early stages of purification, with more solubilisation of the
initial microsomal G551D CFTR by DDM. G551D can be
solubilised to about 50 % yield with DDM (occasionally
above 80 % can be observed) whereas typically 30 %
solubilisation efficiency can be gained for WT CFTR.
Concentrating DDM-purified CFTR proteins after affinity
purification is a problem. The highest concentration that
has been reported in this detergent is about 0.5 mg/mL,
and beyond this precipitates can be observed. This beha-
viour can be monitored with SEC [67]. For DDM-purified
material, SEC purification was not suitable for completely
removing the contaminating proteins [67], but a second
affinity purification step can be applied such as FLAG
affinity chromatography. However, the yield of FLAG
affinity steps is variable and for CFTR it remains about
20–30 % because of low binding affinity. The compro-
mise between yield and purity is commonly encountered
in protein purification and is particularly difficult for
membrane proteins.
Thus, CFTR behaved very differently depending on
which detergent was used in the purification and which
version of the protein was expressed—even though the
purification methods were broadly similar. In the DDM
purification buffer, 1 M salt and 20 % glycerol are used to
maintain the quality of the protein [73, 74] but the solu-
bility and monodispersity are still not sufficient for some
experimental methods such as Cryo-EM and X-ray crys-
tallography. High salt and glycerol are also problems for
Cryo-EM [75] where the presence of these solutes greatly
reduces the contrast between the protein particles and the
background. DDM-purified CFTR also forms a range of
oligomeric but non-identical complexes of up to 30 nm
diameter. These appear to be in a dynamic equilibrium with
monomeric particles because ultrafiltration with a 1 MDa
cutoff device did not remove these larger complexes. Even
when these larger aggregates were removed by SEC, they
reappeared upon concentration and re-passaging down the
SEC column. In conclusion, LPG gives a better solubility
efficiency and prevents aggregation of purified full-length
CFTR [67, 70, 76].
Activity of purified CFTR and stability
The protein purified in LPG is highly mono-disperse as
shown above, but has been reported to have less ATPase
activity compared to the DDM-purified CFTR [67]. Iso-
lated CFTR NBD1 loses its thermal unfolding transition
detected by differential scanning calorimetry in the pres-
ence of LPG above a concentration of 0.05 % w/v [77].
Although this applies to the isolated domain, it does offer a
plausible explanation for the loss of ATPase activity after
LPG14 purification. However, from the thermal unfolding
data, full-length CFTR purified in LPG shows a greater
stability probably because the cytoplasmic NBDs are much
more stable when associated with the other CFTR domains
and where hydrophobic interfacial regions are buried
(Cant, N. University of Manchester, PhD Thesis, 2013).
Thus, it could be argued that stability measurements on
isolated domains could be used to indicate trends in sen-
sitivity to detergents and the effects of mutations on
stability, but that studies on full-length membrane proteins
which include the transmembrane domains are still
essential.
CFTR and G551D CFTR ATPase activity can be com-
pared after purification. The CFTR potentiator VX-770 can
also applied in these studies because of its potentiation of
CFTR G551D channel activity [78–82]. ATPase activity in
CFTR preparations is inevitably susceptible to contami-
nating yeast membrane proteins having ATPase activity,
especially the highly expressed plasma membrane H?-
ATPase [83]. An ATPase activity inhibitor cocktail that
includes Sch28080, sodium thiocyanate (SCN) and
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oligomycin inhibits F-, V- and P-type ATPases, but not
CFTR channel gating [84]; hence, this cocktail can be
employed to suppress the activity of the major yeast
ATPases.
As shown in Fig. 5, VX-770 does not have any effect on
the ATPase activity of the purified and reconstituted G551D
protein, which is consistent with the hypothesis that VX-770
may exert its effect through prolonging channel opening
(which is associated with ATP binding rather than ATP
hydrolysis) [6]. However, Eckford and co-workers [82]
found PKA-phosphorylated G551D CFTR ATPase activity
was stimulated by VX-770. They proposed that VX-770
potentiates defective channel gating in a phosphorylation-
dependent manner whereas PKA phosphorylation did not
seem to affect ATPase activity of purified chicken CFTR
(Dr. Natasha Cant Ph.D thesis, University of Manchester
2013). Reconstitution has been shown to stimulate purified
CFTR’s ATPase activity [67, 82]. Purified WT CFTR has
much higher ATPase activity than G551D CFTR, as
expected. These data are interesting and may be informative
for considering the effects of detergent purification on
activity; however, because the intrinsic ATPase activity of
CFTR is relatively low ([85]—e.g. turnover of 0.1/s) the
presence of even small amounts of highly active contami-
natingATPases could bemisleading and this urges caution in
interpreting these data.
Stability of CFTR as measured by the CPM assay
As discussed above, the CPM assay has been used for
assessing the thermal stability of membrane proteins
[63, 86–88]. The CPM (N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)phenyl]maleimide) dye is a thiol-specific flu-
orophore and it will fluoresce strongly in its thiol-linked
state [89]. When incubated with protein, it will form a
covalent bond with exposed cysteine residues [88]. Upon
thermal denaturation, more cysteine residues will become
surface exposed, resulting in the fluorescence yield
increasing significantly. Only a small amount of protein is
used in the CPM assay because the fluorescence read-out
from the dye is very sensitive. Other advantages are that it
is compatible with several detergents and exhibits a high
signal-to-noise ratio [86–88]. The assay does require the
presence of several Cys residues in a protein and (for
measurement of thermal stability) that some of these Cys
residues are secluded from the dye when the protein is in
the folded state. Hence, it is less applicable to small pro-
teins with few Cys residues. Nevertheless, it can, for
example, be applied to measure the high-temperature
unfolding of GFP which is a small protein, but one that
fortuitously has 2 Cys residues—one buried and one sur-
face exposed.
CPM, like many fluorescent dyes employed in bio-
chemistry, is hydrophobic and photo-sensitive and,
therefore, needs careful handling. It is recommended when
making up CPM stock solutions in DMSO to store these
solutions in glass vials at -20 C and in the dark and then
to dilute to the required experimental concentration just
before use. Whenever possible, it is also advisable to use
glass microsyringes for transfer and dilution of CPM stocks
rather than the plastic tips employed routinely in bio-
chemistry. The binding of CPM to proteins is affected by
thiol-containing reducing agents such as DTT, so these
must be removed from the protein and buffer samples
before undertaking the assay. Reducing agent is normally
present where protein aggregates are a problem, especially
with higher protein concentrations ([1 mg/mL). However,
the sensitivity of the CPM assay means that purified protein
will not normally need to be concentrated, thus removal of
DTT or reducing agent removal can be done just prior to
assay. The concentration of membrane proteins used for the
assay will typically be below 0.1 mg/mL at this stage. It is
important to include a buffer control for all CPM-based
assays. This is particularly important for membrane pro-
teins where buffers will contain detergent in a micellar
form. Although CPM is almost non-fluorescent in water, it
does have a significant fluorescence when it is associated
with detergent micelles.
Fig. 5 Comparison of the ATPase activity of WT and G551D CFTR
with and without VX-770. Purified CFTR was reconstituted with
lipids and its ATPase activity was measured using the Chifflet assay.
The rate was measured at 25 C at a concentration of 2 mM ATP.
These experiments were repeated[3 times and error bars show the
standard error of the mean. An inhibitor cocktail (?inhibitor) was also
employed to check for contaminating ATPases of the V-, H- and
P-type, as described earlier
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Application of the CPM assay to CFTR
There are a total of 18 Cys residues in the full-length WT
human CFTR, 6 predicted to be in the TMDs, 11 in the
NBDs and 1 in the R-region [90]. Examination of CFTR
homology models [90] implies that 5 Cys are exposed in
the outward-facing conformation and 7–8 Cys are exposed
in the inward-facing state—see Fig. 6 [91]. In either con-
formation, there are still predicted to be a majority of Cys
residues buried. At the beginning of the CPM assay, sur-
face-exposed Cys will react with the CPM dye at the initial
incubation temperature (in this case 10 C to favour the
native state). The buried Cys residues will probably only be
exposed when the protein becomes unfolded. These pre-
dictions are based on models that are static snapshots of the
CFTR structure, and CFTR may have more flexibility than
expected due to the presence of the detergent. Neverthe-
less, it is possible to predict that CFTR will have at least 12
Cys that are partly buried and 6 surface-exposed Cys.
Figure 6 shows typical data for CFTR unfolding as
measured using the CPM assay. In aqueous buffers, CPM
fluorescence is low, but greatly increases upon formation of
the covalent adduct with Cys residues in a protein. As
shown in Fig. 6c, there is an increase in CPM fluorescence
when CPM is added to purified CFTR protein due to adduct
formation with the surface-exposed Cys residues (phase
2—Fig. 6c). The very fast initial increase in CPM fluo-
rescence indicated by the number 1 is probably due to
intrinsic CPM fluorescence in the buffer. Although the
CPM fluorescence in aqueous buffers is normally extre-
mely low, when detergent micelles are present, CPM can
partition into the micelle and shows some significant flu-
orescence, as stated above. When CFTR is completely
denatured by Guanidium HCl, the CPM fluorescence
increases in phase ‘2’ to about 60 % of the total signal over
a period of about 30 min at 10 C (Fig. 6c, black line) with
a half-time for the Cys adduct formation of about 10 min at
this temperature. Presumably the increase does not reach
100 % because the membrane-spanning portions of the
protein are relatively resistant to this water-soluble chao-
trope. Subsequent heating of the Guanidium-denatured
protein gives a further increase in CPM fluorescence—
probably due to the exposure of Cys residues that are in the
membrane-spanning portions of the protein. The final
phase (phase 6) of the heating of the protein is charac-
terised by a loss of the fluorescence yield due to thermal
quenching. In contrast, folded CFTR (green line) gives
only a small increase in CPM fluorescence at 10 C (solid
line, Fig. 6), equivalent to about 20 % of the total signal.
This probably represents the small number of surface-ex-
posed Cys residues in the folded CFTR protein—i.e. about
5 of the 20 available residues in the CFTR-GFP construct
(Fig. 6a, b). A large increase in fluorescence is observed
upon heating and thermal denaturation of the protein in the
absence of Guanidium HCl as in this case, about 80 % of
the Cys residues are buried. Hence, the CPM-derived flu-
orescence data are broadly consistent with the available
homology models for CFTR and interestingly are more
consistent with the outward-facing state rather than the
inward-facing conformation. After complete thermal
unfolding of the protein at approximately 78 C, a decrease
in CPM fluorescence yield is again observed due to thermal
quenching. These experiments were performed using an
Avacta Optim Fluorescence Spectrometer coupled to a
Peltier element for heating, but a simple bench-top fluo-
rescence spectrophotometer with an attached water bath for
heating can also be employed.
As the CPM fluorescence at any given temperature is a
convolution of the accessibility/dynamics of available Cys
residues, the kinetics of protein unfolding and CPM–Cys
bond formation (temperature dependent) and the heating
rate, this assay will give differing mid-point temperatures
for protein unfolding depending on these various parame-
ters. Hence, mid-point temperatures estimated for proteins
will be somewhat unreliable and, because of hysteresis,
will likely overestimate the stability of the protein at high
heating rates. Conversely, slow heating rates will tend to
underestimate the mid-point unfolding temperature
because the time dependence of stability at a given mod-
erate temperature will have a stronger influence. Hence, the
assay can be used for comparative purposes as shown in
Figs. 6 and 7, where the experimental parameters such as
heating rate are the same. These data provide evidence that
CFTR material purified in the anionic lyso-lipid LPG and
in the non-ionic detergent DDM have a folded, cooperative
tertiary structure. There are, however, differences in the
unfolding profiles of LPG-purified and DDM-purified
CFTR. Whilst DDM-purified CFTR unfolds in a single
cooperative transition, LPG-purified CFTR shows a two-
phase unfolding profile (Fig. 6d). The latter is charac-
terised by an initial increase in CPM fluorescence between
10 and 35 C, followed by a brief thermal quenching
between 35 and 41 C. This low-temperature and low-
amplitude transition may be due to a localised unfolding of
a sub-domain of CFTR in LPG, or may be due to increased
dynamics of partly buried Cys residues. The main unfold-
ing transitions for CFTR purified in either detergent are
very similar, with mid-point temperatures of about
60–65 C (Fig. 6d).
Molecular dynamics and modelling of Cys residues
in CFTR
Of the 18 Cys residues in CFTR, and the 2 Cys residues in
the GFP construct, some are clearly surface exposed in
both inward- and outward-facing conformational models
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(Fig. 6a, b). In particular, Cys 832 (R-region) and Cys 1458
(C-term) are likely to be in disordered regions of the pro-
tein whilst Cys 48 in the GFP is likely to be surface
exposed. Of the remaining Cys residues, Cys 78 and 647
are very close to regions of the CFTR structure that are
known to be folded, hence may be at least partially buried.
Residues 128, 225, 343, 866 are all in the membrane-
spanning portions of the protein, and hence are likely to be
secluded from CPM by detergent or lipid until the trans-
membrane domains are denatured. Most of the remaining
Cys residues in CFTR are buried within the NBDs,
although three display some exposure to the aqueous
milieu in the outward-facing model (Fig. 6e). These are
Cys residues at positions 276, 592 and 1395, with C592 and
Fig. 6 a, b Homology models for CFTR in the a outward-facing state
(blue ribbons) and b inward-facing state (red ribbons). The locations
of the Cys residues in each model are indicated by the yellow space-
filling atoms, and predictions about their exposure to solvent are listed
below each model. c The unfolding of CFTR by thermal or chemical
denaturation as detected by CPM fluorescence changes. The light
green line shows purified G551D CFTR in an LPG-containing buffer.
Other lines show the same protein but in the presence of 0.25–4 M
Guanidium HCl as indicated by the key, top left. The experiment is
initiated by the injection of CPM dye into a protein-containing cuvette
at 10 C which is then monitored for 30 min (phase A). The sample is
then heated to 90 C (phase B). Various changes in the CPM
fluorescence are indicated: 1 immediate fluorescence from CPM in
buffer (unbound to protein). 2 Kinetics of CPM binding to solvent-
exposed Cys residues. For protein chemically denatured (black line),
nearly all Cys residues are initially exposed. 3 Rise in CPM
fluorescence as thermal motion exposes more Cys residues to solvent
and CPM. 4 Thermal quenching of CPM fluorescence as the sample is
heated (protein is still predominantly folded for the green line). 5
Cooperative thermal unfolding of the entire protein. 6 Continued
thermal quenching of CPM fluorescence after complete unfolding of
the protein. Data point scale represents time (1 min/point—phase A)
and then temperature (phase B—heating rate = 2 C/min with
1 min/point). d The thermal denaturation phase for G551D CFTR
purified in a non-ionic detergent (DDM, blue line) and an anionic
lyso-lipid (LPG, red line). e Two views of the surface of a CFTR
homology model based on the outward-facing Sav1866 structure,
with the sulphur atoms of Cys residues coloured yellow whilst all
other atoms are blue. The TMDs and NBDs are towards the top and
bottom, respectively. C128 and C225 are in membrane-spanning
portions and will probably be buried by surrounding lipid or
detergent. b Deviations of the Cys sulphur atoms for five selected
residues over the time course of a molecular dynamics simulation.
The highly surface-exposed residues C76 (black line) and C592 (red
line) show much greater mobility than the mostly buried residues
C1395 (blue) and C276 (green). Hence, the former two residues are
likely to be labelled by CPM before thermal denaturation. The
completely buried residue C1400 (indigo) shows similar dynamics to
C1395 and C276
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C1395 more buried than C276. Molecular dynamics of
these Cys residues in a homology model for CFTR support
the visual impression that C592 and C1395 are buried
compared to C276 (Fig. 6f). These residues display
dynamics that are similar to the completely buried C1400,
whereas C276 shows much greater dynamics, similar to
that modelled for C78. Hence, molecular dynamics simu-
lation predicts that at least 4 Cys residues will be
sufficiently surface-exposed to be labelled by CPM in the
compact outward-facing configuration, viz., C276, C832,
C1458 and C48 in the GFP tag. In addition, C78 and C647
may be labelled, but these residues are in regions of the
CFTR structure for which little current structural data are
available. Labelling of 4 of the 20 Cys residues in the
purified CFTR-GFP construct with CPM is consistent with
the fluorescence measurements shown in Fig. 6c.
Fig. 7 a Batch-to-batch variability in the thermal denaturation phase
of four batches of DDM-purified G551D CFTR, as detected by CPM
fluorescence changes (each batch was measured three times). Samples
were heated at 2 C/min. b–d Effects of ATP on the thermal
unfolding transition of WT (b), G551D (c) and F508del CFTR
purified in DDM. The presence of ATP stabilises all three constructs.
The increased noise in the data recorded in the presence of ATP is due
to the absorption of excitation light by ATP. F508del CFTR is
globally destabilised versus WT and G551D CFTR by about 8 C.
The midpoint temperatures for the thermal unfolding transition are
shown for each curve and the error for its estimation by the curve
fitting is indicated
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Comparison of CFTR mutations
Thermal unfolding transitions for various purified CFTR
constructs as detected with the CPM assay are shown in
Fig. 7. F508del CFTR has a broader thermal unfolding
transition, whilst G551D CFTR shows a more cooperative
unfolding that was similar to WT CFTR. G551D may be
more stable at the beginning of the thermal denaturation
transition, i.e. in the temperature range that is relevant
physiologically. This may relate to the fact that the G551D
mutation fixes the CFTR channel in a closed state, which
may correlate with a more stable structural state for the
whole protein. A re-scan of the CPM fluorescence for the
thermally denatured protein is routinely monitored and
should give a featureless profile with a negative slope, due
to the thermal quenching of the CPM fluorescence. This
also confirms that thermal unfolding is an irreversible
process.
Batch-to-batch variability and studies of stability
in the presence of small molecules
The effects of the purification procedure may also have a
major influence on the measured stability of a given
membrane protein. Clearly, variability in purification
conditions can result in a protein batch that contains sig-
nificant amounts of already unfolded protein. An
assessment of batch-to-batch variability in the measured
stability is, therefore, important, particularly if results on
the effects of mutations or small molecules on stability are
desired. Figure 7 a illustrates the variability in the
unfolding data across 4 different batches of G551D CFTR
protein purified in the presence of DDM. The error bars
indicate that there will be significant batch-to-batch vari-
ability, even for this well-behaved version of the protein.
Hence, studies on the effects of small molecules on sta-
bility should be performed on the same batch of protein,
and comparisons of the stability of CFTR mutants should
be carried out on several batches of the protein before
conclusions are drawn. Figure 7b–d shows the effects of
ATP addition which gives a significant thermostabilisation
of the purified full-length proteins, as might have been
predicted given similar conclusions for the isolated
nucleotide-binding domains [92]. In this latter study [92],
the isolated WT and F508del NBD1 were both ther-
mostabilised by about 10–15 C by the presence of
millimolar levels of ATP. For the full-length protein, the
thermostabilisation of the protein is less, as shown in
Fig. 7. For F508del CFTR, ATP-induced stabilisation is
greatest, by about 8–10 C in the midpoint transition,
though at lower temperatures, the difference in the CPM-
detected thermal unfolding is more noticeable. This may be
taken as evidence that NBD unfolding may occur at lower
temperatures. For WT and G551D CFTR, the degree of
ATP-mediated themostabilisation is smaller, perhaps indi-
cating that there is an upper limit for stabilisation via ATP
binding to the NBDs.
Summary
CFTR is a typical membrane protein that is somewhat
difficult to express and purify. Stability is a major factor in
the purification and structural analysis of membrane pro-
teins, and CFTR is a good example of how increased
stability can correlate with improved yield, purity and
monodispersity. However, mutations that stabilise a given
membrane protein may not always be associated with
better activity. For example, the G551D mutation in CFTR
improves its properties for structural studies, but by locking
the protein into a channel closed conformation, it blocks its
activity. Hence, it must be acknowledged that for some,
perhaps the majority, of membrane proteins an inherent
instability or flexibility may be crucial for the function of
the protein. Structures of hyper-stabilised versions of
membrane proteins must, therefore, be treated with some
caution as they may bear less relevance for physiology.
Indeed, for CFTR, even though the F508del version of the
protein is by far the least stable, it is also probably the most
relevant in terms of the disease, since loss of stability of
F508del CFTR may be a major factor in its inability to
reach the plasma membrane of the cell.
Acknowledgments The authors wish to thank the CFF (USA) and
CF Trust (UK) for funding. XM was supported by a China Scholar-
ship Council studentship and a University of Manchester President’s
Award. VK was supported by a University of Manchester/ASTAR
Singapore joint studentship. JC was supported by a CF Trust stu-
dentship as part of a Strategic Research Centre award. We also
acknowledge our colleagues on the CFF CFTR 3D structure consor-
tium for invaluable advice and discussions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Mikhailov MV, Campbell JD, de Wet H et al (2005) 3-D struc-
tural and functional characterization of the purified KATP
channel complex Kir6.2-SUR1. EMBO J 24:4166–4175
2. Bryan J, Aguilar-Bryan L (1999) Sulfonylurea receptors: ABC
transporters that regulate ATP-sensitive K(?) channels. Biochim
Biophys Acta 1461:285–303
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability 35
123
3. Bozoky Z, Krzeminski M, Muhandiram R et al (2013) Regulatory
R region of the CFTR chloride channel is a dynamic integrator of
phospho-dependent intra- and intermolecular interactions. Proc
Natl Acad Sci USA 110:E4427–E4436
4. Ostedgaard LS, Baldursson O, Welsh MJ (2001) Regulation of
the cystic fibrosis transmembrane conductance regulator Cl-
channel by its R domain. J Biol Chem 276:7689–7692
5. Wang Y, Wrennal J, Cai Z et al (2014) Understanding how cystic
fibrosis mutations disrupt CFTR function: from single molecules
to animal models. Int J Biochem Cell Biol 52:47–57
6. Vergani P, Lockless SW, Nairn AC et al (2005) CFTR channel
opening by ATP-driven tight dimerization of its nucleotide-
binding domains. Nature 433:876–880
7. Bozoky Z, Krzeminski M, Muhandiram R et al (2013) Regulatory
R region of the CFTR chloride channel is a dynamic integrator of
phospho-dependent intra- and intermolecular interactions. Proc
Natl Acad Sci USA 110:E4427–E4436
8. Ratjen F, Do¨ring G (2003) Cystic fibrosis. Lancet 361:681–689
9. Goodman B, Percy W (2005) CFTR in cystic fibrosis and cholera:
from membrane transport to clinical practice. AJP Adv Physiol
Educ 29:75–82
10. Van Goor F, Hadida S, Grootenhuis PDJ et al (2011) Correction
of the F508del-CFTR protein processing defect in vitro by the
investigational drug VX-809. Proc Natl Acad Sci USA
108:18843–18848
11. Molinski S, Eckford PD, Pasyk S et al (2012) Functional rescue
of F508del-CFTR using small molecule correctors. Front Phar-
macol 3:160
12. He LH, Aleksandrov AA, An JL et al (2015) Restoration of
NBD1 thermal stability is necessary and sufficient to correct delta
F508 CFTR folding and assembly. J Mol Biol 427:106–120
13. Farinha CM, Matos P (2016) Repairing the basic defect in cystic
fibrosis—one approach is not enough. FEBS J 283:246–264
14. Riordan JR (2008) CFTR function and prospects for therapy.
Annu Rev Biochem 77:701–726
15. Serohijos AW, Hegedus T, Aleksandrov AA et al (2008)
Phenylalanine-508 mediates a cytoplasmic-membrane domain
contact in the CFTR 3D structure crucial to assembly and channel
function. Proc Natl Acad Sci USA 105:3256–3261
16. He L, Kota P, Aleksandrov AA et al (2013) Correctors of Del-
taF508 CFTR restore global conformational maturation without
thermally stabilizing the mutant protein. FASEB J Off Publ Fed
Am Soc Exp Biol 27:536–545
17. He L, Aleksandrov AA, Serohijos AW et al (2008) Multiple
membrane-cytoplasmic domain contacts in the cystic fibrosis
transmembrane conductance regulator (CFTR) mediate regula-
tion of channel gating. J Biol Chem 283:26383–26390
18. Ward CL, Omura S, Kopito RR (1995) Degradation of CFTR by
the ubiquitin-proteasome pathway. Cell 83:121–127
19. Kopito RR (1999) Biosynthesis and degradation of CFTR.
Physiol Rev 79:S167–S173
20. Grove DE, Rosser MFN, Watkins RL et al (2011) Analysis of
CFTR folding and degradation in transiently transfected cells.
Cys Fibros Diagn Protoc Vol I Approaches Study Correct CFTR
Defects 741:219–232
21. Cui L, Aleksandrov L, Chang XB et al (2007) Domain interde-
pendence in the biosynthetic assembly of CFTR. J Mol Biol
365:981–994
22. Dalemans W, Barbry P, Champigny G et al (1991) Altered
chloride ion channel kinetics associated with the delta F508
cystic fibrosis mutation. Nature 354:526–528
23. Denning GM, Anderson MP, Amara JF et al (1992) Processing of
mutant cystic fibrosis transmembrane conductance regulator is
temperature-sensitive. Nature 358:761–764
24. Sato S, Ward CL, Krouse ME et al (1996) Glycerol reverses the
misfolding phenotype of the most common cystic fibrosis muta-
tion. J Biol Chem 271:635–638
25. Pedemonte N, Galietta LJ (2012) Pharmacological correctors of
mutant CFTR mistrafficking. Front Pharmacol 3:175
26. Eckford PD, Bear CE (2011) Targeting the regulation of CFTR
channels. Biochem J 435:e1–e4
27. Meacham GC, Patterson C, Zhang WY et al (2001) The Hsc70
co-chaperone CHIP targets immature CFTR for proteasomal
degradation. Nat Cell Biol 3:100–105
28. Becq F, Mettey Y, Gray MA et al (1999) Development of sub-
stituted benzo[c]quinolizinium compounds as novel activators of
the cystic fibrosis chloride channel. J Biol Chem
274:27415–27425
29. Dormer RL, De´rand R, McNeilly CM et al (2001) Correction of
delF508-CFTR activity with benzo(c)quinolizinium compounds
through facilitation of its processing in cystic fibrosis airway
cells. J Cell Sci 114:4073–4081
30. Pedemonte N, Lukacs GL, Du K et al (2005) Small-molecule
correctors of defective deltaF508-CFTR cellular processing
identified by high-throughput screening. J Clin Investig
115:2564–2571
31. Hutt DM, Herman D, Rodrigues AP et al (2009) Reduced histone
deacetylase 7 activity restores function to misfolded CFTR in
cystic fibrosis. Nat Chem Biol 6:25–33
32. Pedemonte N, Tomati V, Sondo E et al (2011) Dual activity of
aminoarylthiazoles on the trafficking and gating defects of the
cystic fibrosis transmembrane conductance regulator chloride
channel caused by cystic fibrosis mutations. J Biol Chem
286:15215–15226
33. Van Goor F, Straley KS, Cao D et al (2006) Rescue of deltaF508-
CFTR trafficking and gating in human cystic fibrosis airway
primary cultures by small molecules. Am J Physiol Lung Cell
Mol Physiol 290:L1117–L1130
34. Van Goor F, Hadida S, Grootenhuis PD et al (2011) Correction of
the F508del-CFTR protein processing defect in vitro by the
investigational drug VX-809. Proc Natl Acad Sci USA
108:18843–18848
35. Haq IJ, Gray MA, Garnett JP et al (2015) Airway surface liquid
homeostasis in cystic fibrosis: pathophysiology and therapeutic
targets. Thorax 71:284–287
36. Clancy JP, Rowe SM, Accurso FJ et al (2012) Results of a phase
IIa study of VX-809, an investigational CFTR corrector com-
pound, in subjects with cystic fibrosis homozygous for the
F508del-CFTR mutation. Thorax 67:12–18
37. Farinha CM, Sousa M, Canato S et al (2015) Increased efficacy of
VX-809 in different cellular systems results from an early sta-
bilization effect of F508del-CFTR. Pharmacol Res Perspect
3:e00152
38. Sampson HM, Robert R, Liao J et al (2011) Identification of a
NBD1-binding pharmacological chaperone that corrects the
trafficking defect of F508del-CFTR. Chem Biol 18:231–242
39. Veit G, Avramescu RG, Perdomo D et al (2014) Some gating
potentiators, including VX-770, diminish deltaF508-CFTR
functional expression. Sci Transl Med 6:246ra297
40. Cholon DM, Quinney NL, Fulcher ML et al (2014) Potentiator
ivacaftor abrogates pharmacological correction of deltaF508
CFTR in cystic fibrosis. Sci Transl Med 6:246ra296
41. Osmanbeyoglu HU, Wehner JA, Carbonell JG et al (2010) Active
machine learning for transmembrane helix prediction. BMC
Bioinform 11(Suppl 1):S58
42. Zhang Z, Kuipers G, Niemiec L et al (2015) High-level pro-
duction of membrane proteins in E. coli BL21(DE3) by omitting
the inducer IPTG. Microb Cell Factories 14:142
36 X. Meng et al.
123
43. Whittaker MM, Whittaker JW (2014) Expression and purification
of recombinant Saccharomyces cerevisiae mitochondrial carrier
protein YGR257Cp (Mtm1p). Protein Expr Purif 93:77–86
44. Lundstrom K, Wagner R, Reinhart C et al (2006) Structural
genomics on membrane proteins: comparison of more than 100
GPCRs in 3 expression systems. J Struct Funct Genomics
7:77–91
45. Garavito RM, Picot D, Loll PJ (1996) Strategies for crystallizing
membrane proteins. J Bioenerg Biomembr 28:13–27
46. Seddon AM, Curnow P, Booth PJ (2004) Membrane proteins,
lipids and detergents: not just a soap opera. Biochim Biophys
Acta 1666:105–117
47. Linke D (2009) Detergents: an overview. Methods Enzymol
463:603–617
48. Krueger-Koplin RD, Sorgen PL, Krueger-Koplin ST et al (2004)
An evaluation of detergents for NMR structural studies of
membrane proteins. J Biomol NMR 28:43–57
49. Fethiere J (2007) Three-dimensional crystallization of membrane
proteins. Methods Mol Biol 363:191–223
50. Kim JM, Wu SP, Tomasiak TM et al (2015) Subnanometre-res-
olution electron cryomicroscopy structure of a heterodimeric
ABC exporter. Nature 517:U396–U598
51. Pollock NL, Satriano L, Zegarra-Moran O et al (2016) Structure
of wild type and mutant F508del CFTR. A small-angle X-ray
scattering study of the protein-detergent complexes. J Struct Biol
194:102–111
52. Le Brun AP, Clifton LA, Holt SA et al (2016) Deuterium labeling
strategies for creating contrast in structure-function studies of
model bacterial outer membranes using neutron reflectometry.
Methods Enzymol 566:231–252
53. Yang ZR, Wang C, Zhou QX et al (2014) Membrane protein
stability can be compromised by detergent interactions with the
extramembranous soluble domains. Protein Sci 23:769–789
54. Aleksandrov LA, Jensen TJ, Cui LY et al (2015) Thermal sta-
bility of purified and reconstituted CFTR in a locked open
channel conformation. Protein Expr Purif 116:159–166
55. Geertsma ER, Groeneveld M, Slotboom DJ et al (2008) Quality
control of overexpressed membrane proteins. Proc Natl Acad Sci
USA 105:5722–5727
56. Hattori M, Hibbs RE, Gouaux E (2012) A fluorescence-detection
size-exclusion chromatography-based thermostability assay for
membrane protein precrystallization screening. Structure 20:
1293–1299
57. Oldham ML, Hite RK, Steffen AM et al (2016) A mechanism of
viral immune evasion revealed by cryo-EM analysis of the TAP
transporter. Nature 529:537–540
58. Bai XC, Yan CY, Yang GH et al (2015) An atomic structure of
human gamma-secretase. Nature 525:212–217
59. Nogales E, Scheres SHW (2015) Cryo-EM: a unique tool for the
visualization of macromolecular complexity. Mol Cell
58:677–689
60. Zhou HX, Cross TA (2013) Influences of membrane mimetic
environments on membrane protein structures. Annu Rev Bio-
phys 42:361–392
61. Tate CG (2012) A crystal clear solution for determining G-pro-
tein-coupled receptor structures. Trends Biochem Sci 37:343–352
62. Moon CP, Fleming KG (2011) Using tryptophan fluorescence to
measure the stability of membrane proteins folded in liposomes.
Methods Enzymol 492:189–211
63. Kohlstaedt M, von der Hocht I, Hilbers F et al (2015) Develop-
ment of a Thermofluor assay for stability determination of
membrane proteins using the Na(?)/H(?) antiporter NhaA and
cytochrome c oxidase. Acta Crystallogr D Biol Crystallogr
71:1112–1122
64. Huang P, Liu Q, Scarborough GA (1998) Lysophosphatidyl-
glycerol: a novel effective detergent for solubilizing and
purifying the cystic fibrosis transmembrane conductance regula-
tor. Anal Biochem 259:89–97
65. Huang P, Stroffekova K, Cuppoletti J et al (1996) Functional
expression of the cystic fibrosis transmembrane conductance
regulator in yeast. Biochim Biophys Acta 1281:80–90
66. O’ryan L, Rimington T, Cant N et al (2012) Expression and
purification of the cystic fibrosis transmembrane conductance
regulator protein in Saccharomyces cerevisiae. Jove J Vis Exp
61:e3860
67. Pollock N, Cant N, Rimington T et al (2014) Purification of the
cystic fibrosis transmembrane conductance regulator protein
expressed in Saccharomyces cerevisiae. J Vis Exp (87):51447.
doi:10.3791/51447
68. Yang Z, Wang C, Zhou Q et al (2014) Membrane protein stability
can be compromised by detergent interactions with the
extramembranous soluble domains. Protein Sci Publ Protein Soc
23:769–789
69. Zhang L, Aleksandrov LA, Zhao Z et al (2009) Architecture of
the cystic fibrosis transmembrane conductance regulator protein
and structural changes associated with phosphorylation and
nucleotide binding. J Struct Biol 167:242–251
70. Huang P, Liu Q, Scarborough GA (1998) Lysophosphatidyl-
glycerol: a novel effective detergent for solubilizing and
purifying the cystic fibrosis transmembrane conductance regula-
tor. Anal Biochem 259:89–97
71. Newstead S, Kim H, von Heijne G et al (2007) High-throughput
fluorescent-based optimization of eukaryotic membrane protein
overexpression and purification in Saccharomyces cerevisiae.
Proc Natl Acad Sci USA 104:13936–13941
72. Newstead S, Ferrandon S, Iwata S (2008) Rationalizing alpha-
helical membrane protein crystallization. Protein Sci 17:466–472
73. Vogel R, Fan GB, Sheves M et al (2001) Salt dependence of the
formation and stability of the signaling state in G protein-coupled
receptors: evidence for the involvement of the Hofmeister effect.
Biochemistry 40:483–493
74. Gekko K, Timasheff SN (1981) Thermodynamic and kinetic
examination of protein stabilization by glycerol. Biochemistry
20:4677–4686
75. Rubinstein JL (2007) Structural analysis of membrane protein
complexes by single particle electron microscopy. Methods
41:409–416
76. Ramjeesingh M, Li C, Garami E et al (1997) A novel procedure
for the efficient purification of the cystic fibrosis transmembrane
conductance regulator (CFTR). Biochem J 327(Pt 1):17–21
77. Yang Z, Wang C, Zhou Q et al (2014) Membrane protein stability
can be compromised by detergent interactions with the
extramembranous soluble domains. Protein Sci 23:769–789
78. Accurso FJ, Rowe SM, Clancy JP et al (2010) Effect of VX-770
in persons with cystic fibrosis and the G551D-CFTR mutation.
N Engl J Med 363:1991–2003
79. Ramsey BW, Davies J, McElvaney NG et al (2011) A CFTR
potentiator in patients with cystic fibrosis and the G551D muta-
tion. N Engl J Med 365:1663–1672
80. Van Goor F, Hadida S, Grootenhuis PD et al (2009) Rescue of CF
airway epithelial cell function in vitro by a CFTR potentiator,
VX-770. Proc Natl Acad Sci USA 106:18825–18830
81. Yu H, Burton B, Huang CJ et al (2012) Ivacaftor potentiation of
multiple CFTR channels with gating mutations. J Cyst Fibros
11:237–245
82. Eckford PD, Li C, Ramjeesingh M et al (2012) Cystic fibrosis
transmembrane conductance regulator (CFTR) potentiator VX-
770 (ivacaftor) opens the defective channel gate of mutant CFTR
in a phosphorylation-dependent but ATP-independent manner.
J Biol Chem 287:36639–36649
83. Carmelo V, Bogaerts P, Sa-Correia I (1996) Activity of plasma
membrane H?-ATPase and expression of PMA1 and PMA2
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability 37
123
genes in Saccharomyces cerevisiae cells grown at optimal and
low pH. Arch Microbiol 166:315–320
84. Schultz BD, Bridges RJ, Frizzell RA (1996) Lack of conventional
ATPase properties in CFTR chloride channel gating. J Membr
Biol 151:63–75
85. Al-Zahrani A, Cant N, Kargas V, Rimington T, Aleksandrov L,
Riordan JR, Ford RC (2015) Structure of the cystic fibrosis
transmembrane conductance regulator in the inward-facing con-
formation revealed by single particle electron microscopy. AIMS
Biophys 2:131–152
86. Lee SC, Bennett BC, Hong WX et al (2013) Steroid-based facial
amphiphiles for stabilization and crystallization of membrane
proteins. Proc Natl Acad Sci USA 110:E1203–E1211
87. Sonoda Y, Newstead S, Hu NJ et al (2011) Benchmarking
membrane protein detergent stability for improving throughput of
high-resolution X-ray structures. Structure 19:17–25
88. Alexandrov AI, Mileni M, Chien EY et al (2008) Microscale
fluorescent thermal stability assay for membrane proteins.
Structure 16:351–359
89. Ayers FC, Warner GL, Smith KL et al (1986) Fluorometric quanti-
tation of cellular and nonprotein thiols. Anal Biochem 154:186–193
90. Mornon JP, Lehn P, Callebaut I (2008) Atomic model of human
cystic fibrosis transmembrane conductance regulator: membrane-
spanning domains and coupling interfaces. Cell Mol Life Sci
65:2594–2612
91. Mornon JP, Lehn P, Callebaut I (2009) Molecular models of the
open and closed states of the whole human CFTR protein. Cell
Mol Life Sci CMLS 66:3469–3486
92. Protasevich I, Yang Z, Wang C et al (2010) Thermal unfolding
studies show the disease causing F508del mutation in CFTR
thermodynamically destabilizes nucleotide-binding domain 1.
Protein Sci Publ Protein Soc 19:1917–1931
38 X. Meng et al.
123
